VANCOUVER, BC, Dec. 16, 2021 /PRNewswire/ -- Sirona Biochem
Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF)
("Sirona") is very pleased to announce that
Linda Pullan of Pullan Consulting
will be providing strategic direction with the negotiations and
licensing of TFC-1067.
Sirona is in the negotiation phase with a global top 10
pharmaceutical company for the rights to TFC-1067. Simultaneously,
the company is completing the legal due diligence regarding
contracts and patents, which is a straightforward task. The pharma
company is advancing on the project as expected and has been
transparent with next steps and timelines.
"We are thrilled to have Pullan Consulting on board to assist us
with this task. Linda has successfully closed 65 pharma/biotech
deals and has advised on many more. She is a renowned
professional in the field," said Howard
Verrico, CEO of Sirona Biochem. "We are dealing with a
pharmaceutical company that is very experienced in licensing
negotiations. The highest level of expertise is needed to obtain
the best outcome. We see this level in Pullan Consulting and look
forward to working with their team to close an optimal deal."
About Sirona Biochem Corp.
Sirona Biochem is a
cosmetic ingredient and drug discovery company with a proprietary
platform technology. Sirona specializes in stabilizing carbohydrate
molecules with the goal of improving efficacy and safety. New
compounds are patented for maximum revenue potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French
national scientific awards and European Union and French government
grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.